Join today and have your say! It’s FREE!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}

Join today with :

or

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Sign in with existing account
Please Try Again
{{ error }}

Sign In With :

or

Password Hint : {{passwordHint}}
Forgot Password?
Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Cutting Edge Cannabinoid Cancer Treatment Enters Final Stage

Proactive Investors, www.proactiveinvestors.co.uk
1 Comment| April 30, 2019




PreveCeutical Medical Inc. (CSE:PREVOTCQB:PRVCFForum) Chief Research Officer Dr Harry Parekh joined Steve Darling from Proactive Investors Vancouver to talk about the companies progress in the development of their sol-gel. Parekh telling proactive the next step they are undertaking with human tissue. He also talked about the progress made in screening peptides isolated from Caribbean Blue Scorpion venom to help combat some of the most aggressive diseases where there exists unmet clinical need, such as cancer.
 




Interested in these industries and sectors?

Receive investor kits and email updates from Stockhouse and directly from these companies.

Healthcare
Technology
Metals & Mining
Technology
Industrials

Interested in these industries and sectors?

You are already a member! Please enter your password to sign in.

Comments

GeneWright
I really hope this will work, too many people I love suffered this awful disease and left us very soon.
(0)
May 8, 2019

Leave a Comment

You must be logged in to access this feature.


×

StockTalk
Get our FREE StockTalk Investor Guides by sector as they are released!

Stay on top of sector specific news, get industry leaders insights and our best content, delivered to your email.

You are already a member! Please enter your password to sign in.